Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AT&T Inc. (T), IMAX Corporation (USA) (IMAX): Monday’s Top Upgrades (and Downgrades)

Page 1 of 2

This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature a pair of upgrades for AT&T Inc. (NYSE:T) and IMAX Corporation (USA) (NYSE:IMAX). But the news isn’t all good, so before we get to those, let’s find out first why…

Liquidity Services, Inc. (NASDAQ:LQDT) is drying up

Shares of surplus, scrap, and salvage merchandise liquidator Liquidity Services, Inc. (NASDAQ:LQDT) are getting vaporized Monday, down nearly 4% as of this writing. For this, you can (at least partly) blame analysts at the Benchmark Company, who cut their price target on Liquidity to $47.

Now granted, $47 is still a pretty optimistic target for Liquidity investors to shoot for. The stock today trades under $34, so a move to $47 would still produce about a 38% profit — not quite as good as the 40%-plus profit Benchmark used to predict, but still an attractive prospect.

Problem is, it’s hard to see how Liquidity gets there. Even after today’s sell-off, the shares still cost nearly 28 times earnings — pricey for a company expected to grow its profits at about 18% per year over the next five years. It’s also worth pointing out that the profits Liquidity’s earning today aren’t of particularly high quality. If Liquidity reported “earning” $40 million last year, its actual cash flows from operations were only $24 million, and, once you subtract capex, actual free cash flow at the firm was less than $17 million.

This all works out to a price-to-free cash flow ratio of 64 times on the stock — far too much for an 18% grower, to my mind. And this suggests that today’s sell-off of 4% could be only the start of a much steeper slide.

AT&T Inc. (NYSE:T): Time to phone home?

AT&T Inc.

Of course, if it’s free cash flow you like, our first upgrade of the day has it in abundance. AT&T Inc. (NYSE:T) generated some $19.8 billion in cold, hard cash profits last year — more than twice its reported $7.4 billion in “net income” under GAAP.

AT&T Inc. (NYSE:T) stock just scored an upgrade to “buy” from analysts at Argus, and over at Canaccord Genuity, they’re talking of improved revenues arising from “strong customer growth in Q2/13.” True, Canaccord also says that earnings could take a tumble due to “promotions and incremental investments.” But even so, the company’s less-than-10-times free cash flow valuation looks attractive in light of the stock’s 6.3% projected growth rate and 5.1% dividend yield.

Fact is, were it not for the fact that AT&T Inc. (NYSE:T)’s carrying more than $70 billion in debt, I might be tempted to take Argus’ advice, and buy some myself. (But since it is carrying all that debt, I think I’ll pass.)

A brighter picture at IMAX Corporation (USA) (NYSE:IMAX)

Finally, we come to IMAX. 3-D movie-viewing has gone definitively mainstream in America, and around the globe. Now, analysts at B. Riley are saying it’s time to capitalize on this fact and add IMAX Corporation (USA) (NYSE:IMAX) to your portfolio. With the stock trading ahead of Riley’s old $24 price target already, the analyst now sees it rising as high as $37 a share over the course of the coming year — a potential 35% profit.

And yet, I just can’t see myself buying this one either. Why not?

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!